The goal of treating chronic kidney disease (CKD) is to slow the progression of renal function decline, control symptoms, prevent complications, and improve patients' quality of life. Treatment strategies should be tailored based on the stage of the disease, overall health status, and individual needs, typically involving a comprehensive plan that includes medications, non-pharmacological therapies, and lifestyle modifications.
Early intervention can effectively delay the progression to end-stage renal failure, making early diagnosis and proactive management crucial. Physicians adjust treatment intensity based on glomerular filtration rate (eGFR) and the degree of metabolic waste accumulation. Monitoring key indicators such as blood pressure, blood glucose, and proteinuria is essential, along with interventions for comorbidities like anemia and mineral metabolism disorders.
The treatment process emphasizes patient participation, including regular follow-up, self-monitoring, and behavioral changes. The healthcare team may include nephrologists, dietitians, and nurses, working together to develop personalized treatment plans. Patients with end-stage renal disease should evaluate the feasibility of dialysis or kidney transplantation and prepare psychologically and physically accordingly.
Controlling blood pressure is key to slowing renal deterioration. Studies show that the target blood pressure is generally below 120/80 mmHg, achieved through antihypertensive medications and lifestyle modifications. Managing proteinuria is also critical, as it indicates glomerular damage; ACE inhibitors (ACEI) or angiotensin receptor blockers (ARB) are used to reduce urinary protein excretion.
For diabetic patients, strict blood glucose control can reduce further kidney damage. Evidence suggests maintaining hemoglobin A1c (HbA1c) below 7%, using insulin or oral hypoglycemic agents. A low-protein diet can also decrease renal filtration burden, with a recommended daily protein intake of 0.8 grams per kilogram of body weight.
anemia is often treated with erythropoietin (EPO) and iron supplements to improve tissue oxygenation. Metabolic acidosis requires bicarbonate supplementation, while hypercalcemia and hyperphosphatemia necessitate phosphate restriction and the use of phosphate binders. Edema can be managed with diuretics, with close monitoring of electrolyte levels to prevent hypotension.
Cardiovascular protection includes the use of statins to lower lipids and regular cardiac function monitoring. Patients with end-stage renal disease may require dialysis; before choosing hemodialysis or peritoneal dialysis, vascular access suitability should be assessed, and the advantages and disadvantages of each method explained.
First-line drugs include ACE inhibitors (ACEI) and angiotensin receptor blockers (ARB), which can reduce proteinuria and protect glomeruli. Common drugs include Losartan and Irbesartan, with regular monitoring of serum creatinine and potassium levels.
Metabolic acidosis is common in end-stage renal disease; sodium bicarbonate buffers blood pH. Phosphate binders such as calcium carbonate and Sevelamer should be taken before meals to bind intestinal phosphate. Active vitamin D3 (Alfacalcidol) can improve calcium-phosphate metabolism, but blood calcium levels should be monitored to prevent hypercalcemia.
For anemia, EPO should be combined with iron supplements, with regular assessment of ferritin and transferrin saturation. New oral agents like Roxadustat stimulate endogenous EPO production, potentially reducing injection frequency.
Hemodialysis requires establishing vascular access, such as an arteriovenous fistula or central venous catheter. Treatment typically occurs three times a week for four hours each session, with attention to infection and fluid overload risks. Peritoneal dialysis uses the peritoneum as a semi-permeable membrane; patients perform daily exchanges at home, suitable for those with mobility issues or preferring home treatment.
Transplant surgery involves tissue matching and immunosuppressive therapy, with a post-operative survival rate of over 95%. Preoperative assessment includes overall health and tolerance to immunosuppressants. Regular anti-rejection therapy is necessary. Living donor kidneys generally have higher survival rates than cadaveric donors, but donor health risks must be evaluated.
A low-protein diet can reduce renal filtration load, with a recommended daily intake of 0.6-0.8 grams per kilogram of body weight. Sodium intake should be limited to below 2000 mg per day to control blood pressure. Patients with hyperphosphatemia should avoid dairy products and nuts, and use phosphate binders to reduce intestinal absorption.
A low-sodium diet can be achieved by substituting processed foods with natural ingredients, such as using herbs instead of salt. Fluid intake should be adjusted based on renal function; for end-stage CKD, 500-1000 mL per day is recommended, tailored to body weight and urine output.
Moderate exercise like walking and swimming for 150 minutes per week can improve cardiovascular health. Avoid vigorous activity that may further damage the kidneys; exercise should be supervised by a physician. Stress management techniques such as mindfulness meditation and breathing exercises can reduce cortisol secretion and lessen renal burden.
Mesenchymal stem cell transplantation has shown potential to repair glomeruli in animal studies, but human clinical trials are ongoing. 3D printing technology is being explored to reconstruct renal tubules; currently in laboratory stages, this may offer tissue-engineered kidney options in the future.
For monogenic hereditary kidney diseases, CRISPR gene editing can repair defective genes, though off-target effects need resolution. Precision medicine involves selecting drugs based on the patient's genotype; for example, those with specific genotypes responding better to ACE inhibitors may be prioritized for such treatment to improve outcomes.
AI algorithms can analyze changes in urine protein and serum creatinine to predict the rate of renal function decline. Wearable devices continuously monitor blood pressure and fluid balance, transmitting data to healthcare teams for early intervention.
Seek immediate medical attention if unexplained rapid weight gain, severe lower limb edema, persistent blood pressure above 140/90 mmHg, or a sudden rise in serum creatinine occurs. If accompanied by cardiovascular symptoms such as chest pain or shortness of breath, exclude uremic cardiomyopathy.
Adverse symptoms such as itching, nausea, or bleeding during medication use should prompt reevaluation of drug dosages and interactions. When creatinine clearance drops below 15 mL/min or uremic symptoms like neurological decline or bleeding tendencies appear, dialysis or transplantation should be considered.
Medication adjustments depend on renal function indicators such as serum creatinine clearance or estimated GFR (eGFR). As kidney function deteriorates, certain drugs (e.g., antibiotics, antihypertensives) may accumulate, increasing toxicity risk. Regular blood and urine tests are recommended, and discussions with the treating physician about drug metabolism are essential. Alternative drugs with lower nephrotoxicity may be necessary.
Is a low-protein diet suitable for all CKD patients? What is the scientific basis?There is evidence supporting low-protein diets (approximately 0.6-0.8 grams per kilogram of body weight per day) to delay renal decline, especially effective after stage 3. This approach reduces renal filtration burden but should be combined with amino acid supplementation to prevent malnutrition. Patients with diabetes or low muscle mass should be evaluated by a dietitian before implementation and should not be blindly followed without professional guidance.
When should patients be referred to a nephrologist for specialized treatment?Referral is necessary if patients exhibit persistent proteinuria (>3 grams/day), a rapid increase in serum creatinine, or complications such as hypertension and anemia. If eGFR remains below 30 mL/min/1.73m² for over three months, it indicates progression to end-stage renal disease, requiring evaluation for dialysis or transplantation.
What personal factors should be considered when choosing between hemodialysis and peritoneal dialysis?Hemodialysis requires regular hospital visits and is suitable for patients with good vascular access; peritoneal dialysis involves daily home exchanges and is preferred for those with mobility issues or seeking flexible schedules. Factors such as infection risk (peritonitis risk in PD), residual renal function, lifestyle, and support systems should be considered in decision-making.
Can traditional Chinese medicine be combined with Western medical treatments? Are there any contraindications?Chinese herbal medicines may contain nephrotoxic components like Aristolochic acid, which can worsen kidney damage when combined with Western drugs. Acupuncture and cupping can be used as adjunct therapies but should be performed by experienced practitioners familiar with kidney disease. Patients should inform their doctors about all herbal and supplementary treatments to minimize drug interactions and adverse effects.
%201.svg)
Copyright © 2025 MedFrontiers. All Rights Reserved.
